1. Home
  2. EMBC vs CSTL Comparison

EMBC vs CSTL Comparison

Compare EMBC & CSTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • EMBC
  • CSTL
  • Stock Information
  • Founded
  • EMBC 1924
  • CSTL 2007
  • Country
  • EMBC United States
  • CSTL United States
  • Employees
  • EMBC N/A
  • CSTL N/A
  • Industry
  • EMBC Medical/Dental Instruments
  • CSTL Medical Specialities
  • Sector
  • EMBC Health Care
  • CSTL Health Care
  • Exchange
  • EMBC Nasdaq
  • CSTL Nasdaq
  • Market Cap
  • EMBC 782.5M
  • CSTL 661.7M
  • IPO Year
  • EMBC N/A
  • CSTL 2019
  • Fundamental
  • Price
  • EMBC $13.66
  • CSTL $24.21
  • Analyst Decision
  • EMBC Buy
  • CSTL Strong Buy
  • Analyst Count
  • EMBC 2
  • CSTL 6
  • Target Price
  • EMBC $18.50
  • CSTL $37.67
  • AVG Volume (30 Days)
  • EMBC 310.8K
  • CSTL 256.3K
  • Earning Date
  • EMBC 11-25-2025
  • CSTL 11-03-2025
  • Dividend Yield
  • EMBC 4.42%
  • CSTL N/A
  • EPS Growth
  • EMBC 18.26
  • CSTL N/A
  • EPS
  • EMBC 1.42
  • CSTL N/A
  • Revenue
  • EMBC $1,102,500,000.00
  • CSTL $346,269,000.00
  • Revenue This Year
  • EMBC N/A
  • CSTL N/A
  • Revenue Next Year
  • EMBC N/A
  • CSTL N/A
  • P/E Ratio
  • EMBC $9.56
  • CSTL N/A
  • Revenue Growth
  • EMBC N/A
  • CSTL 20.40
  • 52 Week Low
  • EMBC $9.20
  • CSTL $14.59
  • 52 Week High
  • EMBC $21.48
  • CSTL $35.84
  • Technical
  • Relative Strength Index (RSI)
  • EMBC 41.91
  • CSTL 56.71
  • Support Level
  • EMBC $13.93
  • CSTL $23.31
  • Resistance Level
  • EMBC $14.43
  • CSTL $24.64
  • Average True Range (ATR)
  • EMBC 0.48
  • CSTL 0.80
  • MACD
  • EMBC -0.03
  • CSTL 0.07
  • Stochastic Oscillator
  • EMBC 23.59
  • CSTL 69.02

About EMBC Embecta Corp.

Embecta Corp is a medical device company focused on providing solutions to improve the health and well-being of people living with diabetes. It has a broad portfolio of marketed products, including various pen needles, syringes, and safety devices, which are complemented by a proprietary digital application designed to assist people with managing their diabetes. The company predominantly sells products to wholesalers and distributors that sell to retail and institutional channels who in turn sell to patients or use the products to deliver insulin injections to patients. It also provides contract manufacturing services. Geographically, the company derives a majority of its revenue from the United States.

About CSTL Castle Biosciences Inc.

Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.

Share on Social Networks: